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Abstract 
               Pulmonary vein isolation (PVI) using radiofrequency current (RFC) ablation is a 
potentially curative treatment option for patients with atrial fibrillation (AF). The shortcomings 
of the RFC technology (technically challenging, long procedure times, complications) steadily 
kindle the interest in new energy sources and catheter designs. High intensity focused ultrasound 
(HIFU) has the ability to precisely focus ultrasound waves in a defined area with a high energy 
density. HIFU balloon catheters (BC) positioned at the PV ostia appear to be an ideal tool to 
transmit the ablation energy in a circumferential manner to the PV ostia and may therefore bear 
substantial   advantage   over   conventional   ablation   catheters   in   PVI   procedures.
            In clinical trials the HIFU BC has shown promising success rates similar to RFC catheter 
ablation for PVI in patients with AF. However, procedure times are still long and serious 
complications   have   been   observed.   Therefore,   it   may   be   a   valuable   alternative   to   the 
conventional techniques in selected patients but further clinical trials have to be initiated.           
            
Key Words:  Atrial fibrillation, pulmonary vein isolation, catheter ablation, high intensity 
focused ultrasound, phrenic nerve palsy.
Introduction
               The discovery of electrical triggers in the pulmonary veins (PV) inducing and 
entertaining atrial fibrillation (AF) initiated the development of new, potentially curative 
treatment strategies for patients with drug refractory paroxysmal AF. Electrical PV isolation 
(PVI) by disconnection of muscular sleeves extending from the left atrium (LA) into the PV is 
currently the most promising approach used in ablation procedures. Radiofrequency current 
(RFC) is the most commonly used energy source to create ablation lesions. In order to achieve 
complete PVI the muscular sleeves are either targeted focally (known as segmental ablation) or 
ablated by circumferential circular lesions at some distance to the veno-atrial junction1-3.  
            Extensive research data and experience is available regarding RFC and is therefore 
exclusively used for PVI in most electrophysiological (EP) laboratories. However, with RFC it 
can be technically challenging to create continuous circumferential linear lesions even if the 
"drag and burn" ablation strategy is applied. This results in time consuming ablation procedures 
increasing the discomfort and risk for complications for both, the patient and the physician.
            In addition, it bears the potential risk for rare but sometimes fatal complications such as 
PV stenosis (1-5%), stroke and atrio-esophageal fistula formation4,5. Additional disadvantages of 
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RFC include the risk of thrombus formation on the ablation electrode or perforations due to 
steam   pops   caused   by   tissue   overheating.                                                          
            The shortcomings of the RFC technology steadily kindle the interest in new energy 
sources and catheter designs. Ideally, the new energy should be safe and effective, e.g. create 
transmyocardial circumferential lesions with a single application.                                               
            High intensity focused ultrasound (HIFU) was originally developed as an extracorporeal 
tool for the treatment of tumors. The ability to precisely focus ultrasound waves in a defined area 
with a high energy density appeared to be an ideal technology to destroy tissue with only 
minimal   collateral   damage.                                                                            
            Balloon mounted catheters positioned at the PV ostia appear to have an ideal shape to 
transmit the ablation energy in a circumferential manner to the neighbored tissue and may 
therefore bear substantial advantage over conventional ablation catheters in PVI procedures.
            In the following review article the concept, technical considerations and first animal and 
clinical   data   using   balloon   mounted   HIFU   catheters   for   PVI   will   be   presented.      
Technical   concept   of   HIFU                                                                      
            HIFU relies on the basic concepts of conventional ultrasound. Mechanical vibrations 
above the threshold of the human hearing are called ultrasound. Ultrasound waves may 
propagate through living tissue and fluids without causing any harm to the cells6. By focusing 
highly energetic ultrasound waves to a well defined volume, local heat rise (usually >56°C and 
up to 80°C) occurs and causes rapid tissue necrosis by coagulative necrosis. Fortunately, a steep 
temperature gradient is observed between the focus and the surrounding tissue allowing for the 
production of sharply demarcated lesions and reducing collateral damage7.                              
            Another mechanism by which HIFU destroys tissue is called acoustic cavitation8. This 
process is based on vibration of cellular structures causing local hyperthermia and mechanical 
stress by bubble formation due to rapid changes in local pressure leading to cell death.   
               In general, extracorporeal and invasive catheter mounted devices are commercially 
available. Since extracorporeal tools are currently not clinically used for cardiac ablation the 
authors will focus on catheter mounted HIFU devices.                                                               
               Ultrasound transducers mounted on angiographic catheters were initially used to 
investigate the feasibility of creating focal lesions in ventricular myocardium9. In order to 
perform more complex ablations such as PVI procedures a further refinement of the catheter 
technology was mandatory. Therefore, balloon mounted ultrasound ablation catheters were 
developed. The basic principle of these balloon catheters (BC) is an ultrasound crystal housed in 
a fluid filled balloon. The Atrionix BC (Atrionix, Inc.) is a non-steerable over-the-wire device 
and   consists   of   a   single   balloon   emitting   non   focused   ultrasound   transradially10.
            Oppositely, the HIFU ablation catheter (ProRhythm, Inc.) consists of a non-compliant 
distal balloon, which is filled with a mixture of water and contrast media (6:1 ratio) and an 
integrated 9 MHz ultrasound crystal. Proximal, a second non-compliant balloon, filled with 
carbon dioxide, forms a parabolic surface at the base of the distal balloon. Thereby, the 
ultrasound waves are reflected in the forward direction, focusing a ring of ultrasound energy 
(sonicating ring) ~4 mm distally to the balloon surface (Figure 1). The new generation of HIFU 
BC are steerable through a pull wire mechanism integrated in the handle of the catheter. Three 
different balloon sizes are available: a 24 mm diameter balloon (20 mm sonicating ring 
diameter), 27 mm diameter balloon (sonicating ring 25 mm diameter) and a 32 mm diameter 
balloon (30 mm sonication ring diameter). The catheter has a central lumen used for PV 
angiography (distal to the balloon) and for insertion of a guide wire (0.035 inch) supporting the 
navigation of the catheter.   
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Figure 1. Basic principle of the HIFU BC (left panel) and a steerable HIFU-BC (right panel). 
See text for details. 
Lesion   formation                                                                        
            A major advantage of HIFU is that no direct tissue contact is needed for the generation of 
the ablation lesion. In several pre-clinical studies it was demonstrated that lesions were formed 
as ultrasound waves are focused in a precisely defined zone leading to a high focal energy 
density11. Consequently, tissue damage is caused by heat reaching maximal tissue temperatures 
of 80° C rather than tissue disruption. Lesion volume depends on sonication time and on the 
initial tissue temperature as well as on the amount of acoustic power12,13. He and colleagues 
demonstrated that transmural lesions (up to 9mm depth) can be achieved in ventricular 
myocardium using catheter mounted ultrasound transducers in beating canine left ventricles9,14. 
Ablation lesions were usually well demarcated without any collateral damage to the surrounding 
tissue15.  
            The balloon mounted HIFU catheter was designed to create circular ablation lesions as 
desired in PVI procedures in order to overcome the above mentioned limitations observed for 
RFC. According to the balloon shape, a circular ablation lesion can be formed by a single 
application of HIFU. In 40-90 sec a complete transmural lesion can be achieved depending on 
the size of the balloon.                                                                                               
Animal   studies                                                                      
            The first experience with HIFU in a beating heart was reported by Zimmer et al.14,16. 
HIFU guided ablations were performed in beating canine hearts using catheter mounted HIFU 
transducers. Later, Strickberger and colleagues performed complete atrio-ventricular (AV) 
junction ablation in ten anesthetized canines17. After thoracotomy a 7.0-MHz diagnostic 
ultrasound probe (Diasonics VST Master Series, Diasonics/Vingmed Ultrasound Inc.) was 
affixed to a spherically focused 1.4 MHz HIFU transducer. From outside the heart the maximum 
ultrasound intensity for ablation (2.8 kW/cm²) was delivered to the AV junction for a total of 30 
sec. Complete AV block was achieved in each of the 10 dogs with a mean of 6.5 (range, 3 to 21) 
HIFU applications. The lesions were distinct and showed a depth of 6.7 ± 3.6 mm, a length of 
5.7 ± 2.5 mm, and a width of 4.7 ± 1.8 mm.  
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            Nakagawa and colleagues investigated the effects of an intracardiac HIFU BC. In a pre-
clinical canine study, acute PVI was achieved using the HIFU BC. PVI persisted in 88% at a 
follow up study performed after 1 week to 3 months11. No thrombus formation at the ablation 
site was observed and lesions were formed even at sites with a lack of balloon to tissue contact. 
In this trial no PV stenosis occurred.                                                                                                     
Clinical   studies                                                                                    
            The first report on PVI by ultrasound ablation in humans was published by Natale and 
co-workers10. Fifteen patients with AF refractory to medication underwent PVI with a non-
steerable BC using non-focused ultrasound (Atrionix, Inc.). The catheter was navigated over-the-
wire, enabling access of the right inferior PV (RIPV) in only one patient. In the remaining 
patients ultrasound ablation was performed only at the right superior and both left PVs. The 
median number of lesions per patient required to isolate 1 pulmonary vein was 4 (range, 1 to 29). 
The mean procedure time was 224 ± 89 minutes (range, 135 to 360 minutes). The mean 
fluoroscopic time was 62 ± 39 minutes (range 37 to 120 minutes). After ablation, no evidence of 
narrowing was seen with repeat venography or follow-up computed tomography scan. However, 
2 patients experienced thrombembolic complications (1 Stroke, 1 transient myocardial ischemia 
by air embolism) and 1 patient experienced right sided phrenic nerve (PN) palsy. After a mean 
follow-up of 35 ± 6 weeks, one third of patients had AF recurrences.                        
            In collaboration with the working group from Oklahoma we reported on the results of 
PVI with the non-steerable HIFU BC (ProRhythm, Inc.) in 27 patients with paroxysmal (19 
patients) or persistent (8 patients) AF18.  PV antrum isolation was attempted using HIFU BC in 
78/104  PVs   (25/27  RSPVs,   all   23LSPVs,   all  23LIPVs,   all  4  left  common  trunks   and 
3/27RIPVs). HIFU BC successfully isolated 68 (87%) of the 78 PV ostia with 1-26 (median 3) 
HIFU applications. The complications included transient bleeding from a distal branch of the left 
superior PV resulting from guide wire manipulation in one patient and right PN injury in another 
patient. No PV stenosis (>50% narrowing) and no LA-esophageal fistula was observed. At the 
12   month   follow-up,   16/27   (59%)   patients   were   free   of   symptomatic   AF   episodes.
            In a consecutive study 15 pts (7 female) with paroxysmal AF were treated with the 
steerable HIFU BC (ProRhythm Inc.)19. The improved steerability increased the success rate for 
complete PVI to 89% (41/46 PVs; Figure 2). After a median follow-up of 387 days (range 120 - 
424 days) 7/12 (58%) of patients were free of AF without antiarrhythmic drugs and in 2 patients 
only a single AF episode was documented, resulting in an overall chronic success of 75%. 
Unfortunately, 2 pts experienced right sided PN palsy, which had not resolved after 12 months.
             Using the steerable balloon all PV (even the RIPV) could be accessed. Meticulous 
mapping of the ablation lesions demonstrated a rather ostial location. As revealed by 3D 
reconstructions of magnetic resonance angiographies of LA and PV the left sided PV often 
display a flat anatomy, resulting from a pronounced mismatch of the maximal and minimal 
diameters20. In addition, the LPV are separated from the LAA only by a narrow myocardial 
ridge. It became evident that by using HIFU BC it remains challenging to achieve complete PVI 
for the LPV because the balloon overlaps into the LAA hindering sonication of the ridge. 
Undersized balloons were frequently used to overcome this limitation.                                   
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Figure 2. HIFU balloon catheter positioned at the right inferior PV (upper panel) and left 
superior PV (lower panel).
Limitations
             In general, HIFU BC ablation can be considered in all patients scheduled for PVI. 
However, patients with common PV ostia with diameters > 30mm may not be eligible because 
the maximal available balloon size is only 30mm.                                                             
            Today, no HIFU catheter is available which can be used for linear (instead of circular) 
ablation. Thus, if additional linear lesions are required, as proposed for patients with permanent 
AF, RFC catheter ablation should be considered.                                                           
            Procedure times for PVI using HIFU were long compared to RFC guided ablations. 
However, it has to be taken into consideration that HIFU BC is an evolving technique with room 
for further improvement. The new generation BC provides the possibility to advance a circular 
mapping catheter via a central lumen obviating the need for repeated deflation and inflation of 
the balloon in order to check for PVI. In fact, at our center 4 patients with paroxysmal AF (3 
male, mean age 58 ± 14 years) were meanwhile treated with this new spiral mapping catheter 
(ProMap, ProRhythm, Inc.), which indeed allowed fast evaluation of ablation success. 15/16 
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PVs were isolated with the HIFU BC and procedure duration was markedly reduced to 127 ± 34 
min. However, one patient experienced right sided PN palsy after sonication of the RSPV.
            In the two published clinical trials 3 phrenic nerve injuries (PNI) were reported among 42 
patients. All PNI occurred during sonication at the RSPV. At the RSPV the PN is in very close 
vicinity to the ostium, and if undersized balloons are used, the energy focus may include the 
PN21. Unfortunately, even after the introduction of CARTO based PN pace mapping one PN 
palsy occurred in the ProMap trial at our center. Thus, it seems to be  advisable to perform 
sonications at the RSPV (1) using oversized balloons and (2) after a  careful evaluation of the 
PN‘s   anatomical   course   reassuring   a   distant   course   to   the   RSPV   ostium.
               A   potential   benefit   of   HIFU   is   the   low   thrombo-embolic   potential.   No   such 
complications were observed in the clinical trials. However, the number of patients may be too 
low   to   asses   the   real   clinical   risk   for   thrombo-embolism   using   HIFU.  
            At present, we are aware of two complications involving the esophagus following HIFU 
treatment (one patient died due to an atrio-esophageal fistula, one patient recovered from 
esophageal laceration). In animal studies it was found that serial HIFU applications can cause 
esophageal lacerations if the balloon is positioned too close to the esophagus and if HIFU is 
delivered unabsorbed within the PV22. This usually occurs when the balloon is undersized and is 
positioned distally to the PV ostium. It is therefore advisable to use oversized balloons, sonicate 
in the LA (not inside the PV) and to maintain a balloon to esophagus distance of > 5mm. 
Monitoring the exact site of sonication and the location of the esophagus may best be possible 
using intravascular cardiac ultrasound (ICE) for visualization. The HIFU-device is presently 
being investigated in a randomized trial enrolling 240 patients in 20 Centers mostly in the USA. 
A similar protocol is evaluated by the ethical committee in 3 European Centers, which will also 
include the latest steerable HIFU catheter which has a small shaft of only 12 French.  
Conclusion
            PVI using HIFU BC for patients with drug-refractory AF is feasible. Due to technical 
shortcomings the procedure times are still long and the patients with large PV ostia (>30mm) 
may not be ideal candidates for HIFU. Nonetheless, in clinical trials this investigational device 
has shown promising success rates similar to RFC catheter ablation. Therefore, it may be a 
valuable alternative to the conventional techniques in selected patients, but further clinical trials 
have to be initiated.
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